Suppr超能文献

c-Src蛋白激酶抑制剂可阻断登革病毒的组装和成熟。

c-Src protein kinase inhibitors block assembly and maturation of dengue virus.

作者信息

Chu J J H, Yang Priscilla L

机构信息

Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.

出版信息

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3520-5. doi: 10.1073/pnas.0611681104. Epub 2007 Feb 21.

Abstract

Dengue virus is a mosquito-borne flavivirus that represents an important emerging infectious disease and is an international health concern. Currently, there is no vaccine or effective antiviral therapy to prevent or to treat dengue virus infection. The slow progress in developing antiviral agents might be alleviated by the availability of efficient high-throughput anti-dengue virus screening assays. In this study, we report an immunofluorescence image-based assay suitable for identification of small molecule inhibitors of dengue virus infection and replication. Using this assay, we have discovered that inhibitors of the c-Src protein kinase exhibit a potent inhibitory effect on dengue virus (serotypes 1-4) and murine flavivirus Modoc. Mechanism of action studies demonstrated that the c-Src protein kinase inhibitor dasatinib prevents the assembly of dengue virions within the virus-induced membranous replication complex. These results demonstrate that this cell-based screen may provide a powerful means to identify new potential targets for anti-dengue drug development while simultaneously providing pharmacological probes to investigate dengue virus-host cell interactions at the biochemical level. Given the simplicity and excellent reproducibility of the assay, it should be useful in high-throughput screens of both small molecule and RNAi libraries when implemented on a robotic image-based high-throughput screen (HTS) platform. Given the reasonable clinical safety of inhibitors such as dasatinib and AZD0530, inhibitors of c-Src protein kinase may have the potential to become a new class of anti-dengue viral therapeutic agents.

摘要

登革病毒是一种由蚊子传播的黄病毒,是一种重要的新出现的传染病,也是国际卫生关注的焦点。目前,尚无疫苗或有效的抗病毒疗法来预防或治疗登革病毒感染。高效高通量抗登革病毒筛选试验的出现可能会缓解抗病毒药物研发进展缓慢的问题。在本研究中,我们报告了一种基于免疫荧光图像的试验,适用于鉴定登革病毒感染和复制的小分子抑制剂。使用该试验,我们发现c-Src蛋白激酶抑制剂对登革病毒(血清型1-4)和鼠黄病毒莫多克表现出强效抑制作用。作用机制研究表明,c-Src蛋白激酶抑制剂达沙替尼可阻止登革病毒粒子在病毒诱导的膜性复制复合物内组装。这些结果表明,这种基于细胞的筛选可能提供一种强大的手段,以识别抗登革药物开发的新潜在靶点,同时提供药理学探针,在生化水平上研究登革病毒与宿主细胞的相互作用。鉴于该试验的简单性和出色的可重复性,当在基于机器人图像的高通量筛选(HTS)平台上实施时,它应可用于小分子和RNAi文库的高通量筛选。鉴于达沙替尼和AZD0530等抑制剂具有合理的临床安全性,c-Src蛋白激酶抑制剂可能有潜力成为一类新的抗登革病毒治疗药物。

相似文献

1
c-Src protein kinase inhibitors block assembly and maturation of dengue virus.c-Src蛋白激酶抑制剂可阻断登革病毒的组装和成熟。
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3520-5. doi: 10.1073/pnas.0611681104. Epub 2007 Feb 21.

引用本文的文献

4
Host centric drug repurposing for viral diseases.以宿主为中心的病毒疾病药物再利用
PLoS Comput Biol. 2025 Apr 2;21(4):e1012876. doi: 10.1371/journal.pcbi.1012876. eCollection 2025 Apr.

本文引用的文献

3
SRC inhibitors in metastatic bone disease.转移性骨病中的Src抑制剂。
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s. doi: 10.1158/1078-0432.CCR-06-0991.
4
Dasatinib.达沙替尼
Nat Rev Drug Discov. 2006 Sep;5(9):717-8. doi: 10.1038/nrd2135.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验